Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
3.970
+0.110 (2.85%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Whitehawk Therapeutics Revenue
In the year 2025, Whitehawk Therapeutics had annual revenue of $7.15M, down -72.50%.
Revenue (ttm)
$7.15M
Revenue Growth
-72.50%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
213.52M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.15M | -18.84M | -72.50% |
| Dec 31, 2024 | 25.98M | 1.63M | 6.69% |
| Dec 31, 2023 | 24.35M | 9.14M | 60.06% |
| Dec 31, 2022 | 15.22M | 14.10M | 1,258.57% |
| Dec 31, 2021 | 1.12M | -13.46M | -92.32% |
| Dec 31, 2020 | 14.58M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 20.16M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Cellectis | 75.11M |
| Compugen | 72.66M |
| Precision BioSciences | 45.07M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 36.49M |
| Camp4 Therapeutics | 3.93M |
| Korro Bio | 3.84M |
WHWK News
- 4 days ago - Whitehawk, Biocytogen collaborate for bispecific antibody ADC development - TheFly
- 4 days ago - Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Wire
- 16 days ago - Whitehawk Therapeutics initiated with a Buy at B. Riley - TheFly
- 4 weeks ago - Whitehawk Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Whitehawk Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Whitehawk Therapeutics presents real-world analysis on SEZ6 - TheFly
- 6 weeks ago - Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 - PRNewsWire
- 6 weeks ago - Whitehawk Therapeutics Registration statement: Registration filing - Filings